Impact of Ibis on Patients With Advanced COPD

Not Applicable

• Conditions: COPD
• Interventions: Behavioral: Digital Therapeutics

• Registration Number: NCT03131622
• Lead Sponsor: Senscio Systems

Brief Summary

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-12
• Study First Submitted: 2016-12-13
• Status Verified: 2017-04
• Study First Submitted QC: 2017-04-24
• Last Update Submitted: 2017-04-24
• Study First Posted: 2017-04-27
• Last Update Posted: 2017-04-27
• Primary Completion: 2018-01
• Study Completion: 2018-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Gold Stage II with a CAT Score above 19
• Gold Stage III/IV with a CAT Score above 14

Exclusion Criteria

• Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Digital Therapeutics	Digital Therapeutics	Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.

Primary Outcome Measures

Name	Time	Method
Reduction in Acute Care Utilization	6 months and then again at 1 year